Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Theralase Technologies Inc. (TLTFF)

Add TLTFF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 7/13/2017 4:11:39 PM - Followers: 68 - Board type: Free - Posts Today: 0


Jan 22, 2014 7:20 AM | about stocks: TLTFF


Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF). They design, develop, manufacture and market, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: First, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; Second, wound care and healing (including non-healing fractures and bone fracture regeneration); And third, research and development into combining patented photodynamic compounds (PDCs) with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses.

The company is currently focused on the commercialization (production, marketing and distribution) of the TLC-2000 Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Key Investment Highlights:

  • Working on breakthrough bladder cancer destruction technology and has achieved tremendous success in pre-clinical trials
    Proven clinical technology (TLC-1000) and commercial therapeutic laser business and brand developed over last 17 years, currently generating ~2M of revenue annually
    Rollout of new TLC-2000 technology in 2014, along with a new recurring revenue business model
    Strategic agreements in place with world renowned institutions to help advance research and mitigate expenses
    Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
    Future technology (patented biofeedback technology and patented PDC cancer destruction)
    IP protection (multiple issued patents)
    Large addressable US markets ($ billions)
    No debt
    Positive cash flow / double digit growth
    Lots of opportunity for short-term and long-term growth (revenue & profit)
    Experienced management team (20+ years)
    Clear vision and execution strategy


Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Theralase PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. Recent lab results have shown that Theralase was able to completely destroy subcutaneous bladder cancer tumors in mouse models. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase.

Key Market Statistics:

  • US bladder cancer treatment annual spending was $3.9 billion in 2012
    70,000 new cases, > 14,000 deaths in the US each year
    386,000 new cases are diagnosed worldwide annually
    Standard treatment unchanged with no new drugs approved since 1998
    5th most common cancer, 4th in men, 8th in women
    Most expensive cancer to treat with a recurrence rate up to 80%
    70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell Carcinoma (TCC)

Theralase PDC Characteristics:

  • Up to 100% cancer cell kill at very low concentrations (< 0.8μM)

(click to enlarge)

  • More effective at killing cancer cells than FDA approved drugs

(668,000x ALA, 198x PHOTOFRIN)

  • Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment

(click to enlarge)

We are VERY IMPRESSED, and VERY EXCITED about these results! In 2012, annual spending for bladder cancer treatment in the US was $3.9 billion, and the current standard of care has been unchanged with no new drugs approved since 1998. Bladder cancer is the most expensive cancer to treat, and has a recurrence rate up to 80%. All of the mice which showed an initial response have remained cancer free, healed without scarring, and have developed normally after only one Theralase PDC treatment. Needless to say, the early results from Theralase look extremely positive. Imagine being able to not only provide treatment for bladder cancer, but to actually cure it, and stop it from coming back! The company is also working on developing further PDCs that can be used to treat a wide variety of other cancers (breast, colon, brain and lung), as well as bacteria and viruses.

  • The general patent protects 1,000s of molecules - essentially a library of PDCs
    Virtually 0% toxicity at high concentrations (> 100μM) leading to ultra-high safety profile
    Activated by laser light providing excellent specificity and selectivity
    Able to treat solid core hypoxic tumors, such as: breast, prostate and lung
    Research outsourced to and performed at world renowned Princess Margaret Cancer Centre
    Patented under numerous US and International Patents:
    Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
    Pending USA Patent Applications: 61/801,674, 13/863,089, 13/36595

To help explain how the procedure works we sketched a diagram:

(click to enlarge)

  1. A catheter is inserted into the patient
    The PDC is injected and saturates within the patient's bladder, penetrating the cellular membrane (DNA localizing)
    Fiber optics cables are inserted up the catheter into the bladder
    Using laser technology, light is irradiated 360°
    The entire procedure takes about 2 - 3 hours

Theralase is currently completing the validation of the orthotopic rat model, a dose toxicity study, GMP drug manufacture, and FDA Investigational New Drug (IND) application. The next phase is to complete an FDA phase 1/2a human clinical study with FDA breakthrough status, and then to execute a strategic partnership agreement with big pharmaceutical (pharma) company (upfront payments, co-development funds, annual recurring revenue streams).

Industry comparables:

(click to enlarge)

(click to enlarge)

Deals with comparable big pharma companies have yielded anywhere from $466M to $1B plus royalties.


The thing is, by the time clinical trials have been completed (assuming they're successful), Theralase will be trading many multiples higher than today. Look how excited investors got when Theralase first released PDC breast cancer results during January 2010, the intraday high for TLT was $1.39/share:

Read More :

Themes: Biotechnology, Micro Capitalization, Growth Opportunity, Pharmaceuticals, Cancer, Laser Technology, Photo Dynamic Compounds (PDCs) Stocks: TLTFF
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TLTFF News: Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug 03/15/2017 07:02:00 AM
TLTFF News: Theralase Anti-Cancer Technology Picks Up Steam 01/06/2015 07:00:00 AM
TLTFF News: Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM 03/12/2014 07:05:00 AM
TLTFF News: Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 03/14/2013 07:00:04 AM
#2931   Just get us out of the pennies and MIKE22CA 07/13/17 04:11:39 PM
#2930   Also remember that Roger is the largest share itsallgood11 07/13/17 03:31:27 PM
#2929   What he said is they might just release itsallgood11 07/13/17 03:24:34 PM
#2928   So they haven't even treated the 1st patient CUIN2 07/13/17 03:11:31 PM
#2927   Just talked with Roger White. Good stuff. itsallgood11 07/13/17 12:35:27 PM
#2926   Next mon-tues. Were golden. A high majority MIKE22CA 07/13/17 10:13:26 AM
#2925   i love a sale. heavymetal 07/13/17 07:04:19 AM
#2924   When it looks this good, and yet the Gene_Simmons 07/05/17 04:36:57 PM
#2923   *shakes head* MIKE22CA 07/05/17 08:20:31 AM
#2922   Theralase Releases Annual and Special Meeting Videos suerte88 07/05/17 08:13:39 AM
#2921   Try 4 weeks.. if the 3 cystoscopes MIKE22CA 07/02/17 11:58:38 PM
#2920   You guys can't see the forest for all Gene_Simmons 07/02/17 04:24:47 PM
#2919   Post from vestor who went to the AGM -3 07/02/17 10:36:31 AM
#2918   I agree - only two things will significantly MasterSalix 07/02/17 09:23:53 AM
#2917   I remember after all that waiting the tlc2000 itsallgood11 07/02/17 08:20:21 AM
#2916   Yes, but that was before all of the CUIN2 07/01/17 06:03:40 PM
#2915   my thanks CUIN. phew....not great news for the citoyen 07/01/17 05:32:38 PM
#2914   Here you go CUIN2 07/01/17 05:08:28 PM
#2913   CUIN or anyone: can you provide a link citoyen 07/01/17 05:04:14 PM
#2912   the way i see it. heavymetal 07/01/17 04:44:05 PM
#2911   The study of the 6 with the therapeutic CUIN2 07/01/17 01:23:10 PM
#2910   It won't be, wasn't it 180 day study? Kgs68 07/01/17 01:18:48 PM
#2909   Good points and understood. My biggest problem/issue is that CUIN2 07/01/17 01:10:49 PM
#2908   I see you as a poster on both Kgs68 07/01/17 12:59:46 PM
#2907   I have been long here a while. Without CUIN2 07/01/17 10:44:29 AM
#2906   I have been long here a while. Without getting CUIN2 07/01/17 10:34:15 AM
#2902   Cant post on stock house. Cuin23 research itsallgood11 06/30/17 10:00:08 PM
#2901   Cancer could be big for Theralase. Why CUIN2 06/29/17 03:05:39 PM
#2900   This arthritis news seems a potentially big development citoyen 06/29/17 02:33:35 PM
#2899   BREAKING NEWS Its in mice, preclinical research LJ Silver 06/29/17 07:35:22 AM
#2898   up 10% this morning: heavymetal 06/27/17 09:48:39 AM
#2897   on stockhouse, yes. heavymetal 06/27/17 07:13:50 AM
#2896   Anyone else having trouble logging in to TLT -3 06/27/17 06:39:07 AM
#2895   Nice, need some big ones this week MIKE22CA 06/26/17 07:38:44 AM
#2894   Theralase Researcher Granted Second US Patent for Novel CUIN2 06/26/17 07:12:52 AM
#2893   the problem with this stock is there is heavymetal 06/25/17 11:01:52 AM
#2892   if the higher dose on 6 new patients heavymetal 06/22/17 02:43:36 PM
#2891   Well I hope the trip in New York MIKE22CA 06/20/17 09:17:25 AM
#2890   Something is up with trades that occurred almost CUIN2 06/19/17 08:37:13 PM
#2889   Will be interesting for sure CUIN2 06/15/17 10:31:15 AM
#2888   Well perhaps this climb is the first biggy. MIKE22CA 06/15/17 10:29:01 AM
#2887   tltff on us exchange is up 15% right now. heavymetal 06/15/17 09:37:19 AM
#2886   "LAISSEZ LE BON TEMPS ROULER" heavymetal 06/15/17 08:33:04 AM
#2885   Great news! Today Theralase is in NYC CUIN2 06/15/17 07:59:26 AM
#2884   Theralase Presents Phosphorescent Photosensitizers at International World Congre Anesthesia 2007 06/15/17 07:58:41 AM
#2883   "Dr. Kaspler concluded in his presentation that TLD-1433 is: heavymetal 06/14/17 04:19:36 PM
#2882   Theralase Presents X-Ray Activation at International World Congress Toronto, Anesthesia 2007 06/14/17 09:22:34 AM
#2881 MIKE22CA 06/13/17 09:18:49 PM
#2880   Conclusions of the presentation included: TLD-1433 has good selectivity CUIN2 06/13/17 07:55:01 PM
#2879   I don't think they did. CUIN2 06/13/17 06:49:08 PM